Genmab Analyst Price Targets - Benzinga

Genmab AS

GMABNASDAQ

Trade with Public

Trade with Public

$36.05

-0.60-1.64%

Dern. MÀJ: Oct 8, 5:39 PM

$36.04

-0.61-1.66%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Genmab Analyst Price Targets - Benzinga

Genmab Analyst Price Targets

Wall Street analyst price targets and consensus rating for Genmab (GMAB).

Price Target Range — 13 Quarters

Analyst Consensus — 13 Analysts

12Buy

1Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$41Upside to Avg. PT+13.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Truist Securities	Asthika Goonewardene	PT Raise	Buy	$40→$45
Oct 7, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$54→$58
Oct 7, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$40→$50
Oct 5, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$45→$54
Sep 14, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40
Aug 7, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$40→$42
Jul 22, 2026	TD Cowen	Yaron Werber	Upgrade	Hold→Buy	$32→$43
Jul 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$38→$40
Jun 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$38
Apr 30, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$40→$38
Mar 27, 2026	Wolfe Research	Kalpit Patel	Initiate	Outperform	$32
Mar 2, 2026	Wells Fargo	Eva Fortea Verdejo	Initiate	Overweight	$40
Feb 23, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$45→$40
Feb 18, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$39→$40
Feb 17, 2026	Jefferies	Benjamin Jackson	Reinstates	Buy	$42
Feb 16, 2026	Morgan Stanley	Judah Frommer	Reinstates	Equal-Weight	$34
Jan 28, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$39
Jan 20, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$41→$39
Nov 10, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$40→$41
Nov 7, 2025	Truist Securities	Asthika Goonewardene	PT Cut	Buy	$49→$48

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Genmab, Raises Price Target to $45

Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $45.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Genmab, Raises Price Target to $58

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $54 to $58.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $50

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $50.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Genmab, Raises Price Target to $54

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $54.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Genmab, Raises Price Target to $42

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $42.

Benzinga Newsdesk